NeuroDex develops blood-based biomarkers utilizing cell-specific extracellular vesicles to identify patients with synucleinopathies associated with neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This technology provides essential tools for researchers and clinicians to accelerate the development of effective diagnostics and therapies.
Funding
Funding not disclosed
TAFounders
Product
Problem
Diagnosing and monitoring synucleinopathies, such as Parkinson's disease, Alzheimer's disease, and Lewy body dementia, currently lacks effective blood-based biomarkers, hindering early detection and treatment development. Traditional diagnostic methods often rely on invasive procedures or late-stage clinical manifestations. This absence of accessible and reliable biomarkers impedes the progress of precision medicine for neurodegenerative diseases.
Solution
NeuroDex is developing blood-based biomarker assays that leverage cell-specific extracellular vesicles (exosomes) to identify patients with synucleinopathies, even in the early stages of disease. The technology isolates exosomes from plasma and detects protein markers associated with neurodegenerative conditions on the surface or within the exosomes. These assays provide a less invasive and more accessible method for assessing neurological pathologies. By offering a suite of biomarker tools, NeuroDex aims to accelerate the development of effective diagnostics and therapies for diseases like Lewy body dementia, Alzheimer’s disease, Parkinson’s disease, and ALS.
Target Audience
The primary target audience includes researchers and clinicians focused on neurodegenerative diseases, particularly those working on early diagnosis, drug development, and precision medicine approaches for synucleinopathies.
Features
- Proprietary technology for isolating cell-specific exosomes from plasma
- Detection of protein markers of synucleinopathies within or on the surface of exosomes
- Development of blood-based biomarker assays for early disease detection
- Potential for identifying and differentiating various forms of dementia
- Tools for monitoring disease progression and treatment response